Sex, Gender, and the Regulation of Prescription Drugs: Omissions and Opportunities
International Journal of Environmental Research and Public Health · 08.02.2023 · 20 (4) · 2962
DOI: 10.3390/ijerph20042962 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Environmental Research and Public Health, online erschienen am 08.02.2023. Verfasst von Lorraine Greaves und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre of Excellence for Women's Health, Vancouver, BC V6H 3N1, Canada. Hauptthemen laut MEDLINE: Prescription Drugs. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research.
Abstract (Originalsprache)
The regulation of prescription drugs is an important health, safety, and equity issue. However, regulatory processes do not always consider evidence on sex, gender, and factors such as age and race, omissions that advocates have highlighted for several decades. Assessing the impact of sex-related factors is critical to ensuring drug safety and efficacy for females and males, and for informing clinical product monographs and consumer information. Gender-related factors affect prescribing, access to drugs, needs and desires for specific prescribed therapies. This article draws on a policy-research partnership project that examined the lifecycle management of prescription drugs in Canada using a sex and gender-based analysis plus (SGBA+) lens. In the same time period, Health Canada created a Scientific Advisory Committee on Health Products for Women, in part to examine drug regulation. We report on grey literature and selected regulatory documents to illustrate the extent to which sex and gender-based analysis plus (SGBA+) is utilized in regulation and policy. We identify omissions in the management of prescription drugs, and name opportunities for improvements by integrating SGBA+ into drug sponsor applications, clinical trials development, and pharmacovigilance. We report on recent efforts to incorporate sex disaggregated data and recommend ways that the management of prescription drugs can benefit from more integration of sex, gender, and equity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre of Excellence for Women's Health, Vancouver, BC V6H 3N1, Canada.
- School of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
- Women's College Hospital, Toronto, ON M5S 1B2, Canada.
- School of Pharmacy, University of Waterloo, Kitchener, ON N2G 1C5, Canada.
- Neil John Maclean Health Sciences Library, University of Manitoba, Winnipeg, MB R3M 3M1, Canada.
- College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3M 3M1, Canada.
ORCID-Profile: Lorraine Greaves, Mê-Linh Lê
Förderung
- CIHR
- Canadian Institutes of Health Research
Zitieren
APA
Greaves, L., Brabete, A. C., Maximos, M., Huber, E., Li, A., Lê, M. L., Eltonsy, S., & Boscoe, M. (2023). Sex, Gender, and the Regulation of Prescription Drugs: Omissions and Opportunities. International Journal of Environmental Research and Public Health, 20(4), 2962. https://doi.org/10.3390/ijerph20042962
Vancouver
Greaves L, Brabete AC, Maximos M, Huber E, Li A, Lê ML, et al. Sex, Gender, and the Regulation of Prescription Drugs: Omissions and Opportunities. International Journal of Environmental Research and Public Health. 2023;20(4):2962. doi:10.3390/ijerph20042962
BibTeX
@article{Greaves2023,
author = {Greaves, Lorraine and Brabete, Andreea C and Maximos, Mira and Huber, Ella and Li, Alice and Lê, Mê-Linh and Eltonsy, Sherif and Boscoe, Madeline},
title = {Sex, Gender, and the Regulation of Prescription Drugs: Omissions and Opportunities},
journal = {International Journal of Environmental Research and Public Health},
year = {2023},
volume = {20},
number = {4},
pages = {2962},
doi = {10.3390/ijerph20042962}
}
EUVIMED